Cell-based detection and differentiation of lung cancer

Details Cell-based detection and differentiation of lung cancer Cell-based detection and differentiation of lung cancer

2005-09-06

2005-09-06

Canella, Karen A. (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S006120, C435S007100, C530S388800, C530S389700, C530S391100, C536S024310, C436S064000

Reexamination Certificate

active

06939670

ABSTRACT:
The present invention provides a method for detecting and differentiating disease states with high sensitivity and specificity. The method allows for a determination of whether a cell-based sample contains abnormal cells and, for certain diseases, is capable of determining the histologic type of disease present. The method detects changes in the level and pattern of expression of the molecular markers in the cell-based sample. Panel selection and validation procedures are also provided.

REFERENCES:
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 4853770 (1989-08-01), Schneller
patent: 5543291 (1996-08-01), Keyomarsi et al.
patent: 5731162 (1998-03-01), Gatti et al.
patent: 5997866 (1999-12-01), Johnson et al.
patent: 6007996 (1999-12-01), McNamara et al.
patent: 6335170 (2002-01-01), Orntoft
patent: 2002/0192228 (2002-12-01), Hanash
patent: 0 727 664 (1996-08-01), None
patent: WO87/06620 (1987-11-01), None
patent: WO94/24560 (1994-10-01), None
patent: WO98/28622 (1998-07-01), None
patent: WO99/21014 (1999-04-01), None
patent: WO99/64631 (1999-12-01), None
patent: WO 00/55180 (2000-09-01), None
patent: WO01/36674 (2001-05-01), None
patent: WO02/08764 (2002-01-01), None
Roig et al (Anticancer Research, 1993, vol. 13, pp. 2457-2463.
Burke et al (Human Pathology, 1999, vol. 30, pp. 158-167).
60/121,124.
Guddo et al (J Clin Pathol, 1998, vol. 51, pp. 667-671).
Malusecka et al (Anticancer Research, 2001, 21, vol. 1015-1021).
Dessy et al (Virchows Archive, Mar 2000, vol. 436, pp. 289-296).
Puglisi et al (Cancer Letters, 2001, vol. 162, pp. 97-103).
Schlom (Monoclonal Antibodies, In: Molecular Foundations of Oncology, 1991, pp. 95-134).
Flam et al., “Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Gueriri endovesical immunotherapy for superficial bladder tumors”, Abstract, European Urology, pp. 338-342, vol. 17, No. 4.
Duray et al., “Immunohistochemical phenotyping of malignant melanoma. A procedure whose time has come in pathology practice”, Abstract, Pathology Annual, pp. 351-377, vol. 25 Pt 2, 1990.
Gazdar et al., “Biological, Molecular, and Clinical Markers for the Diagnosis and Typing of Lung Cancer”, Abstract, Immunol. Ser, pp. 453-468, vol. 53, 1990.
Terada et al., “N -Ras Gene-Mutations in Childhood Acute Non-Lymphoblastic Leukemia”, Abstract, Leukemia Research, pp. 935-941, vol. 15, No. 10, 1991.
Imamura et al., “Detection of High-Incidence of N-Ras Oncogene Point Mutations in Acute Myelogenous Leukemia”, Abstract, American Journal of Hematology, pp. 151-153, vol. 43, No. 2, Jun. 1993.
Wood et al., “Immunocytochemical and Differentiation of Reactive Hyperplasia from Follicular Lymphoma Using Monoclonal Antibodies to Cell-Surface and Proliferation-Related Markers”, Abstract, Applied Immunohistochemistry, pp. 48-53, vol. 2, Nol. 1, Spring 1994.
Jacquemier et al, “P53 Immunochemical Analysis in Breast-Cancer with 4 Monoclonal-Antibodies-Comparison of Stating and PCR-SSCP Results”, Abstract, British Journal of Cancer, pp. 846-852, vol. 69, No. 5, May 1994.
Granberg et al, “Prognostic markers in bronchial carcinoid tumors”, Abstract, Proc Annu Meet Am Assoc Cancer Res, vol. 38, A774, 1997.
Pastorino et al, “Immunochemical markers in stage I lung cancer: relevance to prognosis”, Abstract, Journal of Clinical Oncology, pp. 2858-2865, vol. 15, No. 8, Aug. 1997.
Harpole et al, “A biological risk model for stage I lung cancer: Immunohistochemcial analysis of 408 patients with the use of ten molecular markers”, Abstract, Journal of Thoracic and Cardiovascular Surgery, pp. 736-742, vol. 117, No. 4, Apr. 1999.
Piao et al., “Frequent loss xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and auxiliary lymph node status”, Abstract, Genes, Chromosomes & Cancer, pp. 262-269, vol. 33, No. 3, Mar. 2002.
Fritsche et al., “Tumor markers and pattern recognition analysis: A new diagnostic tool for cancer”, Abstract, Journal of Clinical Ligand Assay, pp. 11-15, vol. 25, Nol, 1, Spring 2002.
Wu et al., “Value of Combined determination of tumor marker for histological type of lung cancer by pattern recognition”, Abstract, Henan Yilce Daxue Xuebao, pp. 214-217, vol. 35, No. 3, 2000.
Pohl et al., “Neural network evaluation of multiple tumor markers for diagnosis of ovarian cancer using three different sets of patients”, Abstract, 3rd International Conference of the Mediterranean Society of Tumor Marker Oncology, Oct. 26-29, 1994.
Lansford et al., “Resolution of multiple green fluorescent protein color variants and dyes using two-photon microscopy and imaging spectroscopy”, Abstract, Journal of Biomedical Optics, pp. 311-318, vol. 6, No. 3, Jul. 2001.
So et al., “Two-photon deep tissue ex vivo imaging of mouse dermal and subcutaneous structures”, Abstract, Optics Express, pp. 339-350, vol. 3, No. 9, Oct. 26, 1998.
Tockman et al., “Sensitive and Specific Monoclonal Antibody Recognition of Human Lung Cancer Antigen or Preserved Sputum Cells: A New Approach to Early Lung Cancer Detection,” Journal of Clinical Oncology, vol. 6, No. 11, Nov. 1988, pp. 1685-1693, XP000614978.
Lozano et al., “Immunocytochemistry in the Differential Diagnosis of Serous Effusions: A Comparative Evaluation of Eight Monoclonal Antibodies in Papanicolaou Stained Smears”, Cancer Cytopathology, vol. 93, No. 1, Feb. 25, 2001, pp. 68-72, XP009002477.
Frisman et al., “Immunocytochemistry in the Differential Diagnosis of Effusions: Use of Logistic Regression to Select a Panel of Antibodies to Distinguish Adenocarcinomas from Mesothelial Proliferations,” Modern Pathology, vol. 6, No. 2, 1993, pp. 179-184, XP009002474.
Leers et al., “E-Cadherin and Calretinin: A Useful Combination of Immunochemical Markers for Differentiation Between Mesothelioma and Metastatic Adenocarcinoma,” Histopathology (Oxford), vol. 32, No. 3, Mar. 1998, pp. 209-216. XP002224146.
Skov et al., “Differentiation of Adenocarcinoma of the Lung and Malignant Mesothelioma: Predictive Value and Reproducibility of Immunoreactive Antibodies,” Histopathology (Oxford), vol. 25, No. 5, 1994, pp. 431-437, XP009002475.
Neft et al., “Concurrent Fluorescence in Situ Hybridization and immunocytochemistry for the Detection of Chromosome Aberrations in Exfoliated Bronchial Epithelial Cells,” ACTA Cytological, International Academy of Cytology, Chicago, IL, vol. 41, No. 6, 1997, pp. 1769-1773, XP000961317.
Gonzalez-Lois et al., “Combined Use of Novel Epithelial (MOC-31) and Mesothelial (HBME-1) Immunohistochemical Markers for Optimal First Line Diagnostic Distinction Between Mesothelioma and Metastatic Carcinoma in Pleura,” Histopathology (Oxford), vol. 38, No. 6, Jun. 2001, pp. 528-534, XP002224147.
Kallakury et al., “The Prognostic Significance of Proliferation-Associated Nucleolar Protein p120 Expression in Prostate Adenocarcinoma: A Comparison with Cyclins A and B1, Ki-67, Proliferating Cell Nuclear Antigen, and p34cdc2,” CANCER, vol. 85, No. 7, Apr. 1, 1999, pp. 1569-1576, XP-002235530.
Mitas et al., “Quantitative Real-Time RT-PCR Detection of Breast Cancer Micrometastasis Using a Multigene Marker Panel,” International Journal of Cancer, vol. 93, No. 2, 2001, pp. 162-171.
Volm et al., “Prognostic Value of ERBB-1, VEGF, Cyclin A, FOS, JUN and MYC in Patients with Squamous Cell Lung Carcinomas,” British Journal of Cancer, vol. 77, No. 4, Feb. 1998, pp. 663-669, XP009007843.
Bejarano et al., “Surfactant Proteins and Thyroid Transcription Factor-1 in Pulmonary and Breast Carcinomas,” Modern Pathology, vol. 9, No. 4, 1996, pp. 445-452, XP009007792.
Gaspar et al., “Quantitative Immunohistochemical Analyses of the Expression of E-Cadherin, Thrombomodulin, CD44H and CD44v6 in Primary Tumours of Pharynx/Larynx S

Affiliated with

Also associated with

Rating

Cell-based detection and differentiation of lung cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell-based detection and differentiation of lung cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-based detection and differentiation of lung cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3398443